更换对比剂对既往有钆对比剂轻度速发型过敏反应患者的预防效果
回顾性分析185例既往对钆对比剂发生轻度速发型过敏反应的患者,共再次暴露397次,总体复发率19.6%。更换致敏对比剂可显著降低复发率(6.9% vs 25.8%,P<0.001),且更换为不同分子结构类别时复发率最低(6.2%);单剂预给药未见显著预防效果(20.4% vs 17.3%,P=0.509)。
要点
- 更换致敏钆对比剂可显著降低速发型过敏反应复发率(6.9% vs 25.8%,P<0.001)。
- 更换为不同分子结构类别对比剂时复发率最低(6.2%)。
- 单剂预给药对复发无显著预防效果(20.4% vs 17.3%,P=0.509)。
核心结论
- 更换致敏对比剂可降低既往有钆对比剂轻度速发型过敏反应患者的复发风险,尤其是更换为不同分子结构类别时;单剂预给药未显示显著降低复发率差异。
研究设计与样本
- 回顾性分析2012年10月至2017年7月期间既往对钆对比剂发生轻度速发型过敏反应并随后接受增强磁共振检查的患者,共185例,再次暴露397次;通过机构对比剂监测系统回顾性获取预给药和对比剂选择数据;钆对比剂按分子结构分为大环离子型、大环非离子型和线性离子型3类。
诊断标准与关键数值
- 预给药方案为静脉注射氯苯那敏4 mg(对比剂给药前30分钟)或静脉注射甲泼尼龙琥珀酸钠40 mg加氯苯那敏4 mg(对比剂给药前1小时);总体复发率19.6%(78/397);更换致敏对比剂组复发率6.9%(9/130) vs 复用致敏对比剂组25.8%(69/267),P<0.001;更换为不同分子结构类别组6.2%(7/113) vs 更换为相同分子结构组11.8%(2/17) vs 复用致敏对比剂组25.8%(69/267),趋势χ检验P<0.001;单剂预给药组20.4%(17/98) vs 未预给药组17.3%(61/299),P=0.509;更换对比剂基础上加用预给药组7.2%(7/97) vs 仅更换对比剂组6.1%(2/33),P=0.821。
临床应用与阅片要点
- 作者结论认为,更换致敏对比剂可降低既往有钆对比剂轻度速发型过敏反应患者的复发风险,尤其更换为不同分子结构类别时;但单剂预给药未显示显著降低复发率差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Currently, the prevention of recurrent immediate hypersensitivity reactions (HSRs) to contrast media (CM) requests premedication and changing the culprit contrast agent. However, strategies for the prevention of immediate HSRs to gadolinium-based magnetic resonance contrast agents (GBCAs) have not yet been established. This study aimed to evaluate the effectiveness of changing the contrast agent and single-dose premedication for HSR recurrence prevention in patients with a history of mild immediate HSR to GBCA.
MATERIALS AND METHODS: The outcomes of patients with mild immediate HSR to GBCA who subsequently underwent enhanced magnetic resonance imaging between October 2012 and July 2017 were analyzed. The institutional CM monitoring system was retrospectively reviewed, and data on the application of premedication and choice of CM were obtained. Gadolinium-based magnetic resonance contrast agents were classified into 3 classes according to their molecular structure (macrocyclic ionic, macrocyclic nonionic, and linear ionic). Intravenous chlorpheniramine 4 mg, 30 minutes before the GBCA administration, or intravenous methylprednisolone sodium succinate 40 mg plus chlorpheniramine 4 mg, 1 hour before the GBCA administration, was administrated as premedication regimen. Recurrence rates of immediate HSR were compared according to prevention strategies.
RESULTS: A total of 185 patients with a history of mild immediate HSR to GBCA were re-exposed to GBCA 397 times during the study period. The overall recurrence rate was 19.6% (78/397). Changing the culprit GBCA significantly reduced the recurrence rate, compared with reusing the culprit GBCA (6.9%, 9/130 and 25.8%, 69/267; P < 0.001). The recurrence rate was lowest when the GBCA was changed to a different molecular structure class from the culprit agent, followed by changing to CM with the same molecular structure and reusing the culprit GBCA (6.2%, 7/113 vs 11.8%, 2/17 vs 25.8%, 69/267; P < 0.001 with χ test for trend). Single-dose premedication demonstrated no significant prophylactic effect on recurrence (20.4%, 17/98 vs 17.3%, 61/299 with and without premedication, respectively; P = 0.509). Premedication in addition to changing CM also showed no additional prophylactic effect (7.2%, 7/97 and 6.1%, 2/33, respectively; P = 0.821).
CONCLUSIONS: Changing the CM from the culprit agent could reduce the chance of HSR recurrence in patients with prior mild immediate HSR to GBCA, especially when the CM was changed to one of a different molecular structure class. However, single-dose premedication administration did not show significant HSR recurrence rate difference.
引用
- Ryoo CH, Choi YH, Cheon JE, et al. Preventive Effect of Changing Contrast Media in Patients With A Prior Mild Immediate Hypersensitivity Reaction to Gadolinium-Based Contrast Agent. Invest Radiol. 2019. PMID: 31033674. doi:10.1097/RLI.0000000000000573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。